Danaher Corporation $DHR Shares Sold by Agate Pass Investment Management LLC

Agate Pass Investment Management LLC lowered its position in shares of Danaher Corporation (NYSE:DHR) by 2.6% in the second quarter, HoldingsChannel.com reports. The fund owned 13,251 shares of the conglomerate’s stock after selling 354 shares during the quarter. Agate Pass Investment Management LLC’s holdings in Danaher were worth $2,618,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Zone Wealth Advisors LLC lifted its position in Danaher by 12.8% during the 2nd quarter. Blue Zone Wealth Advisors LLC now owns 21,683 shares of the conglomerate’s stock worth $4,283,000 after acquiring an additional 2,462 shares during the period. PDS Planning Inc lifted its position in Danaher by 11.1% during the 2nd quarter. PDS Planning Inc now owns 4,207 shares of the conglomerate’s stock worth $831,000 after acquiring an additional 420 shares during the period. Blue Trust Inc. lifted its holdings in shares of Danaher by 1.0% in the 2nd quarter. Blue Trust Inc. now owns 10,937 shares of the conglomerate’s stock valued at $2,161,000 after buying an additional 106 shares during the period. 3Chopt Investment Partners LLC lifted its holdings in shares of Danaher by 4.2% in the 2nd quarter. 3Chopt Investment Partners LLC now owns 3,688 shares of the conglomerate’s stock valued at $730,000 after buying an additional 150 shares during the period. Finally, Horizon Bancorp Inc. IN acquired a new position in shares of Danaher in the 2nd quarter valued at about $99,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of Danaher stock opened at $202.53 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41. The business has a 50-day moving average price of $200.66 and a 200 day moving average price of $197.25. The firm has a market cap of $145.02 billion, a PE ratio of 43.09, a P/E/G ratio of 2.91 and a beta of 0.77.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same quarter in the previous year, the business earned $1.72 EPS. Danaher’s revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s payout ratio is 27.23%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DHR. Barclays reissued an “overweight” rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Redburn Partners set a $220.00 price objective on Danaher in a report on Wednesday. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Finally, Evercore ISI boosted their price objective on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $244.60.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.